No Data
No Data
Dyne Therapeutics(DYN.US) Director Sells US$3.99 Million in Common Stock
Dyne Therapeutics(DYN.US) Director Sells US$4.08 Million in Common Stock
Dyne Therapeutics(DYN.US) Director Sells US$3.27 Million in Common Stock
Piper Sandler Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $53
Dyne Therapeutics Initiated at Outperform by RBC Capital
Dyne Therapeutics Analyst Ratings